Stemina Biomarker Discovery, Inc.
Stemina Biomarker Discovery is dedicated to improving human health through innovative, cell-based assays that utilize human embryonic stem cells, induced pluripotent stem cells, and metabolomics. The company develops and commercializes molecular biomarkers and in vitro toxicity assays to enhance drug safety, reduce animal testing, and support regulatory acceptance. Its mission is to help organizations develop the safest compounds possible by providing predictive toxicology solutions, including assays for developmental and cardiotoxicity, and diagnostic tools for neurological disorders such as autism.
Industries
Nr. of Employees
small (1-50)
Stemina Biomarker Discovery, Inc.
504 S. Rosa Road, Suite 150, Madison, WI 53719
Patents
Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
US-10473641-B2
View DetailsPredicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
US-10209240-B2
View Details
Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
US-10473641-B2
View DetailsPredicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
US-10209240-B2
View DetailsProducts
Biomarker-based developmental toxicity assay (service/product)
A screening assay that uses human pluripotent stem cells and metabolite biomarker ratios to indicate potential developmental toxicity and prioritize compounds.
Cardiotoxicity screening assay (metabolite-based)
An assay using iPSC-derived cardiomyocytes and a targeted metabolite panel to predict cardiotoxicity potential and classify known cardiotoxic and non-cardiotoxic compounds.
Blood-based metabolomics diagnostic assay for neurodevelopmental disorders
A clinical assay developed from cohort studies to detect metabolomic signatures associated with neurodevelopmental conditions for earlier diagnostic support.
Biomarker-based developmental toxicity assay (service/product)
A screening assay that uses human pluripotent stem cells and metabolite biomarker ratios to indicate potential developmental toxicity and prioritize compounds.
Cardiotoxicity screening assay (metabolite-based)
An assay using iPSC-derived cardiomyocytes and a targeted metabolite panel to predict cardiotoxicity potential and classify known cardiotoxic and non-cardiotoxic compounds.
Blood-based metabolomics diagnostic assay for neurodevelopmental disorders
A clinical assay developed from cohort studies to detect metabolomic signatures associated with neurodevelopmental conditions for earlier diagnostic support.
Services
Laboratory service using human pluripotent stem cell assays and metabolite biomarkers to assess developmental toxicity potential of compounds.
Service utilizing iPSC-derived cardiomyocytes and targeted metabolite readouts to detect structural and functional cardiotoxicity signals.
Project-specific study design, execution, data analysis, and interpretation for toxicology screening and biomarker discovery.
Translation of metabolomics-derived biomarker signatures from cohort studies into blood-based diagnostic assays for neurodevelopmental conditions.
Laboratory service using human pluripotent stem cell assays and metabolite biomarkers to assess developmental toxicity potential of compounds.
Service utilizing iPSC-derived cardiomyocytes and targeted metabolite readouts to detect structural and functional cardiotoxicity signals.
Project-specific study design, execution, data analysis, and interpretation for toxicology screening and biomarker discovery.
Translation of metabolomics-derived biomarker signatures from cohort studies into blood-based diagnostic assays for neurodevelopmental conditions.
Expertise Areas
- In vitro toxicology screening
- Developmental toxicology
- Cardiac safety assessment
- Metabolomics and biomarker discovery
Key Technologies
- Liquid chromatography–mass spectrometry (LC–MS)
- Targeted and non‑targeted metabolomics
- Human embryonic and induced pluripotent stem cells (hES/iPS)
- iPSC-derived cardiomyocytes
News & Updates
A study demonstrating the use of Stemina’s devTOX _quick_ Predict assay to predict developmental effects of chemicals in a concentration-dependent manner.
A presentation on using Stemina’s assays to predict developmental and reproductive toxicity hazards earlier in chemical development.
A study demonstrating the ranking of retinoid analogues' developmental toxicity using a human iPS cell assay.
Research on predicting cardiotoxic effects of tyrosine kinase inhibitors using an in vitro assay.
Stemina provides a key platform supporting EPA’s programs, including an assay on human embryonic stem cell metabolism.
A predictive assay for developmental toxicity based on human embryonic stem cells and metabolomics.
A study demonstrating the use of Stemina’s devTOX _quick_ Predict assay to predict developmental effects of chemicals in a concentration-dependent manner.
A presentation on using Stemina’s assays to predict developmental and reproductive toxicity hazards earlier in chemical development.
A study demonstrating the ranking of retinoid analogues' developmental toxicity using a human iPS cell assay.
Research on predicting cardiotoxic effects of tyrosine kinase inhibitors using an in vitro assay.
Stemina provides a key platform supporting EPA’s programs, including an assay on human embryonic stem cell metabolism.
A predictive assay for developmental toxicity based on human embryonic stem cells and metabolomics.